Journal
MOLECULAR CANCER THERAPEUTICS
Volume 21, Issue 6, Pages 925-935Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1535-7163.MCT-21-0619
Keywords
-
Categories
Funding
- NIH [F30 GM142199-01]
- Louisiana State University Health Sciences Center - Shreveport Weinberger Lab Startup funding
- Cherie-Ann Nathan Distinguished Professor of Otolaryngology/Head & Neck Surgery Endowed Professorship
Ask authors/readers for more resources
Anaplastic thyroid cancer (ATC) is a highly aggressive form of cancer with few effective treatment options. YM155, previously identified as a survivin inhibitor, showed promise in killing ATC cells in laboratory and animal studies. However, clinical trials did not show a correlation between survivin expression and response to YM155. Despite this setback, alternative mechanisms for YM155 are currently being investigated.
Anaplastic thyroid cancer (ATC) is among the most aggressive of human cancers, and currently there are few effective treatments for most patients. YM155, first identified as a survivin inhibitor, was highlighted in a high-throughput screen performed by the National Cancer Institute, killing ATC cells in vitro and in vivo. However, there was no association between survivin expression and response to YM155 in clinical trials, and YM155 has been mostly abandoned for development despite favorable pharmacokinetic and toxicity profiles. Currently, alternative mechanisms are being explored for YM155 by a number of groups. In this study, ATC patient samples show overexpression of topoisom
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available